 BriaCell Therapeutics Corp NASDAQ: BCTX has announced the presentation of results from clinical studies evaluating its lead product candidate, Bria-IMT, at the American Association for Cancer Research AACR Annual Meeting 2021. The findings indicate disease control in advanced breast cancer patients, including stable disease SD, partial responses PR, or complete responses CR. 